PKD Foundation , Critical Path Institute (C-Path), and CDISC are expanding their collaboration to develop Version 2.0 of the Therapeutic Area User Guide for Polycystic Kidney Disease (TAUG-PKD)
Public source
Publisher name
Public post
This PKD Awareness Day, we’re helping build the foundation for the next generation of PKD breakthroughs. The PKD Foundation, Critical Path Institute (C-Path), and CDISC…
Company
PKD Foundation
We give hope. We fund research, advocate for patients and build a community for all impacted by PKD.
- Industry
- Non-profit Organizations
- Location
- Kansas City, US
- Company size
- 51–200 employees
About PKD Foundation
The PKD Foundation is a not-for-profit organization dedicated to finding treatments and a cure for polycystic kidney disease (PKD). Our mission: We give hope. We fund research, advocate for patients and build a community for those affected by PKD. Our vision: #endPKD The PKD Foundation founded in 1982 by Joseph H. Bruening and Jared J. Grantham, M.D., and is headquartered in Kansas City, MO PKD Connect: Whether you are looking for information, resources or just a shoulder to lean on, PKD Connect gives you the support to keep hope within reach. Visit PKD Connect at connect.pkdcure.org
See moreLatest activity
Latest activity from PKD Foundation
8 signals
Products & Services
PKD Foundation launched the ADPKD Registry as a patient-powered engine for discovery that captures real-world insights from people living with PKD.
Presence & Recognition
PKD Foundation President and CEO Susan Bushnell shared why the generational impact of polycystic kidney disease is a driving force behind the mission.
Presence & Recognition
PKD Foundation volunteers officially recognized September 4 as PKD Awareness Day
Discover more
Similar signals
Similar public activity from other companies.
Partnerships
CDISC
CDISC announced an expanded collaboration with the PKD Foundation and Critical Path Institute to develop Version 2.0 of the Therapeutic Area User Guide for Polycystic Kidney Disease.
Research & Knowledge
Critical Path Institute (C-Path)
Critical Path Institute (C-Path) researchers are closer than ever to developing the first targeted treatments for Autosomal Dominant Tubulointerstitial Kidney Disease caused by UMOD and MUC1 gene variants.
Partnerships
Digital Medicine Society (DiMe)
Digital Medicine Society (DiMe) welcomed Pfizer to the Composite and Multimodal Endpoints for Pediatric Rare Disease project.
Partnerships
Global Genes
Global Genes announced a new partnership with Citizen Health to power RARE-X, its rare disease data collection program.
Partnerships
Citizen Health